Drug Profile

Solid tumour vaccine - Northwest Biotherapeutics

Alternative Names: DCVax^®-Direct; DCVax^®-Direct adjuvant cancer therapy; DCVax^®-Head & Neck; DCVax^®-Liver; DCVax^®-Lung; DCVax^®-Pancreas

Latest Information Update: 03 Sep 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Northwest Biotherapeutics
Class Antineoplastics; Cancer vaccines; Dendritic cell vaccines; Immunotherapies
Mechanism of Action Immunostimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

27 Aug 2025 Northwest Biotherapeutics plans a phase II trial for Solid tumours in 2025
13 Oct 2023 Northwest Biotherapeutics plans a phase-II trials for Solid tumours
11 Mar 2023 Northwest Biotherapeutics plans a phase II trial in Solid tumours (Inoperable/Unresectable)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com